The biotechnology company, founded in 2019 and based in Kyoto, Japan, specializes in the research, development, production, and marketing of cell therapy for chronic kidney diseases. Their drugs utilize core seeds technology, including pluripotent stem cells that produce erythropoietin (EPO), ureteral blast cells, and surface markers specific to nephron progenitor cells. By leveraging these technologies, Rege Nephro aims to reduce the number of patients who require dialysis. Their regenerative therapeutic products include nephron progenitor cells for renal cells, erythropoietin-producing cells for renal anemia, and urethroplasty for the development of kidney organoids.